Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00171769 · ClinicalTrials.gov registry record · Phase 3
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
A Phase 3 study of Persistent Nonvalvular Atrial Fibrillation, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT00171769 is a Phase 3 study of Persistent Nonvalvular Atrial Fibrillation that has completed, run by Novartis. The registered enrollment target is 200 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00171769, a Phase 3 study of Persistent Nonvalvular Atrial Fibrillation, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
Conditions Studied
Interventions
- DRUG Certoparin
Study Locations (2)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Other
- - Investigative Centers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00171769
The ClinicalTrials.gov registry entry for NCT00171769 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Persistent Nonvalvular Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Certoparin is the first listed.
NCT00171769 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00171769 about?
NCT00171769 is a clinical study titled "Atrial Fibrillation Feasibility Certoparin Trial - AFFECT". This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
What is the current status of trial NCT00171769?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2005-04.
What conditions does trial NCT00171769 study?
This clinical trial studies the following conditions: Persistent Nonvalvular Atrial Fibrillation.
What interventions are being tested in trial NCT00171769?
The interventions under investigation include: Certoparin (DRUG).
Who is sponsoring clinical trial NCT00171769?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00171769 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.